To date, the role of SGLT‐2 inhibitors on ED is not sufficiently investigated; in fact, only data from a study on a T2DM rat model are available, the Goto–Kakizaki rat treated with empagliflozin, with or without acute intravenous injection of sildenafil109: rats treated with empagliflozin showed an improvement of EF versus the placebo group, due to a better response of corpora cavernosa to the NO effect, limiting oxidative activity. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.